Challenges and Promises of Developing Thrombin Receptor Antagonists

Recent Patents on Cardiovascular Drug Discovery

Volumn 5, Issue 3, 2010, Pages 162-170

  Yang, Jing ^a   Xu, Ke ^a   Seiffert, Dietmar ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Antiplatelet; Antithrombotic; Atherothrombosis; GPCR antagonist; PAR 1; PAR 4; Platelet; Protease activated receptor; Thrombin receptor; Thrombosis

Indexed keywords

3A,4,4A,5,6,7,8,8A,9,9A DECAHYDRO N [4 [2 [5 (3 FLUOROPHENYL) 2 PYRIDYL]VINYL] 3 METHYL 1 OXO 3H BENZO[F]ISOBENZOFURAN 7 YL]CARBAMIC ACID ETHYL ESTER; E 5555; F 16357; F 16618; PIPERAZINE DERIVATIVE; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 4; PROTEINASE INHIBITOR; PYRIDAZINE DERIVATIVE; THROMBIN RECEPTOR; THROMBIN RECEPTOR ACTIVATING PEPTIDE; THROMBIN RECEPTOR ANTAGONIST; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; YD 3;

ARTICLE; BLEEDING; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; HEMOSTASIS; HUMAN; NONHUMAN; PATENT; PRIORITY JOURNAL; THROMBOSIS;

ADMINISTRATION, ORAL; ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; IMINES; LACTONES; PLATELET AGGREGATION INHIBITORS; PYRIDINES; RECEPTOR, PAR-1; RECEPTORS, THROMBIN; THROMBIN; THROMBOSIS;

EID: 78650034184     PISSN: 15748901     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489010793351980     Document Type: Article

References (122)

1. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, et al. Heart disease and stroke statistics-2009 update: A report from the american heart association statistics committee and stroke statistics subcommittee. Circulation 2009; 119: e21-181.
2. Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007; 357: 2482-94.
3. Bhatt DL, Topol EJ. Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov 2003; 2:15-28.
4. Gurbel PA, Bliden KP, Samara W, Yoho JA, Hayes K, Fissha MZ, et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J Am Coll Cardiol 2005; 46:1827-32.
5. L'Allier PL, Ducrocq G, Pranno N, Noble S, Ibrahim R, Gregoire JC, et al. Clopidogrel 600-mg double loading dose achieves stronger platelet inhibition than conventional regimens: Results from the PREPAIR randomized study. J Am Coll Cardiol 2008; 51:1066-72.
6. Dangas G, Mehran R, Guagliumi G, Caixeta A, Witzenbichler B, Aoki J, et al. Role of clopidogrel loading dose in patients with STsegment elevation myocardial infarction undergoing primary angioplasty: Results from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial. J Am Coll Cardiol 2009. 54:1438-46.
7. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-15.
8. Wiviott SD, Trenk D, Frelinger AL, O'Donoghue M, Neumann FJ, Michelson AD, et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: The prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation-thrombolysis in myocardial infarction 44 trial. Circulation 2007; 116: 2923-32.
9. Brandt JT, Payne CD, Wiviott SD, Weerakkody G, Farid NA, Small DS, et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: Magnitude of platelet inhibition is related to active metabolite formation. Am Heart J 2007; 153(66): e69-16.
10. James S, Akerblom A, Cannon CP, Emanuelsson H, Husted S, Katus H, et al. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J 2009; 157: 599-605.
11. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361:1045-57.
12. Husted S, van Giezen JJ. Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist. Cardiovasc Ther 2009; 27: 259-74.
13. Storey RF, Thornton MS, Lawrance R, Husted S, Wickens M, Emanuelsson H, et al. Ticagrelor yields consistent dose-dependent inhibition of ADP-induced platelet aggregation in patients with atherosclerotic disease regardless of genotypic variations in P2RY12, P2RY1, and ITGB3. Platelets 2009; 20: 341-8.
14. Cohen M. Expanding the recognition and assessment of bleeding events associated with antiplatelet therapy in primary care. Mayo Clin Proc 2009; 84:149-60.
15. Steinhubl SR, Kastrati A, Berger PB. Variation in the definitions of bleeding in clinical trials of patients with acute coronary syndromes and undergoing percutaneous coronary interventions and its impact on the apparent safety of antithrombotic drugs. Am Heart J 2007; 154: 3-11.
16. Schenone M, Furie BC, Furie B. The blood coagulation cascade. Curr Opin Hematol 2004; 11: 272-7.
17. Mann KG, Orfeo T, Butenas S, Undas A, Brummel-Ziedins K. Blood coagulation dynamics in haemostasis. Hamostaseologie 2009; 29: 7-16.
18. Jackson SP. The growing complexity of platelet aggregation. Blood 2007; 109: 5087-95.
19. Mann KG, Butenas S, Brummel K. The dynamics of thrombin formation. Arterioscler Thromb Vasc Biol 2003; 23:17-25.
20. Brass LF. Thrombin and platelet activation. Chest 2003; 124:18S-25S.
21. Hathcock JJ. Flow effects on coagulation and thrombosis. Arterioscler Thromb Vasc Biol 2006; 26:1729-37.
22. Brass LF, Zhu L, Stalker TJ. Novel therapeutic targets at the platelet vascular interface. Arterioscler Thromb Vasc Biol 2008; 28: 43-50.
23. Gresele P, Falcinelli E, Momi S. Potentiation and priming of platelet activation: A potential target for antiplatelet therapy. Trends Pharmacol Sci 2008; 29: 352-60.
24. Nesbitt WS, Westein E, Tovar-Lopez FJ, Tolouei E, Mitchell A, Fu J, et al. A shear gradient-dependent platelet aggregation mechanism drives thrombus formation. Nat Med 2009; 15: 665-73.
25. Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA 1989; 86: 2839-43.
26. Ardissino D, Merlini PA, Arlens R, Coppola R, Bramucci E, Lucreziotti S, et al. Tissue factor in human coronary atherosclerotic plaques. Clin Chim Acta 2000; 291: 235-40.
27. Toschi V, Gallo R, Lettino M, Fallon JT, Gertz SD, Fernandez- Ortiz A, et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 1997; 95: 594-9.
28. Badimon JJ, Lettino M, Toschi V, Fuster V, Berrozpe M, Chesebro JH, et al. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions. Circulation 1999; 99: 1780-7.
29. Coughlin SR. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost 2005; 3: 1800-14.
30. Kahn ML, Nakanishi-Matsui M, Shapiro MJ, Ishihara H, Coughlin SR. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest 1999; 103: 879-87.
31. Ramstrom S, Oberg KV, Akerstrom F, Enstrom C, Lindahl TL. Platelet PAR1 receptor density-correlation to platelet activation response and changes in exposure after platelet activation. Thromb Res 2008; 121: 681-8.
32. Brass LF, Vassallo RR, Jr., Belmonte E, Ahuja M, Cichowski K, Hoxie JA. Structure and function of the human platelet thrombin receptor. Studies using monoclonal antibodies directed against a defined domain within the receptor N terminus. J Biol Chem 1992; 267: 13795-8.
33. Scarborough RM, Naughton MA, Teng W, Hung DT, Rose J, Vu TK, et al. Tethered ligand agonist peptides. Structural requirements for thrombin receptor activation reveal mechanism of proteolytic unmasking of agonist function. J Biol Chem 1992; 267: 13146-9.
34. Brass LF, Pizarro S, Ahuja M, Belmonte E, Blanchard N, Stadel JM, et al. Changes in the structure and function of the human thrombin receptor during receptor activation, internalization, and recycling. J Biol Chem 1994; 269: 2943-52.
35. Hoxie JA, Ahuja M, Belmonte E, Pizarro S, Parton R, Brass LF. Internalization and recycling of activated thrombin receptors. J Biol Chem 1993; 268: 13756-63.
36. Molino M, Bainton DF, Hoxie JA, Coughlin SR, Brass LF. Thrombin receptors on human platelets. Initial localization and subsequent redistribution during platelet activation. J Biol Chem 1997; 272: 6011-7.
37. Holinstat M, Voss B, Bilodeau ML, Hamm HE. Protease-activated receptors differentially regulate human platelet activation through a phosphatidic acid-dependent pathway. Mol Pharmacol 2007; 71: 686-94.
38. 2+ mobilization and synergistic P2Y12 receptor activation. J Biol Chem 2006; 281: 26665-74.
39. Voss B, McLaughlin JN, Holinstat M, Zent R, Hamm HE. PAR1, but not PAR4, activates human platelets through a Gi/o/phosphoinositide-3 kinase signaling axis. Mol Pharmacol 2007; 71:1399-1406.
40. Bilodeau ML, Hamm HE. Regulation of protease-activated receptor (PAR) 1 and PAR4 signaling in human platelets by compartmentalized cyclic nucleotide actions. J Pharmacol Exp Ther 2007; 322: 778-88.
41. Covic L, Gresser AL, Kuliopulos A. Biphasic kinetics of activation and signaling for PAR1 and PAR4 thrombin receptors in platelets. Biochemistry 2000; 39: 5458-67.
42. Ishii K, Hein L, Kobilka B, Coughlin SR. Kinetics of thrombin receptor cleavage on intact cells. Relation to signaling. J Biol Chem 1993; 268: 9780-6.
43. Shapiro MJ, Weiss EJ, Faruqi TR, Coughlin SR. Protease-activated receptors 1 and 4 are shut off with distinct kinetics after activation by thrombin. J Biol Chem 2000; 275: 25216-21.
44. Leger AJ, Jacques SL, Badar J, Kaneider NC, Derian CK, Andrade-Gordon P, et al. Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis. Circulation 2006; 113: 1244-54.
45. Nieman MT. Protease-activated receptor 4 uses anionic residues to interact with alpha-thrombin in the absence or presence of proteaseactivated receptor 1. Biochemistry 2008; 47: 13279-86.
46. Seeley S, Covic L, Jacques SL, Sudmeier J, Baleja JD, Kuliopulos A. Structural basis for thrombin activation of a protease-activated receptor: Inhibition of intramolecular liganding. Chem Biol 2003; 10: 1033-41.
47. Covic L, Singh C, Smith H, Kuliopulos A. Role of the PAR4 thrombin receptor in stabilizing platelet-platelet aggregates as revealed by a patient with Hermansky-Pudlak syndrome. Thromb Haemost 2002; 87: 722-7.
48. Mazharian A, Roger S, Berrou E, Adam F, Kauskot A, Nurden P, et al. Protease-activating receptor-4 induces full platelet spreading on a fibrinogen matrix: involvement of ERK2 and p38 and Ca2+ mobilization. J Biol Chem 2007; 282: 5478-87.
49. Hollenberg MD, Saifeddine M. Proteinase-activated receptor 4 (PAR4): Activation and inhibition of rat platelet aggregation by PAR4-derived peptides. Can J Physiol Pharmacol 2001; 79: 439-42.
50. Covic L, Misra M, Badar J, Singh C, Kuliopulos A. Pepducinbased intervention of thrombin-receptor signaling and systemic platelet activation. Nat Med 2002; 8:1161-5.
51. Ofosu FA, Dewar L, Craven SJ, Song Y, Cedrone A, Freedman J, 2nd, et al. Coordinate activation of human platelet protease-activated receptor-1 and -4 in response to subnanomolar alphathrombin. J Biol Chem 2008; 283: 26886-93.
52. Sangawa T, Nogi T, Takagi J. A murine monoclonal antibody that binds N-terminal extracellular segment of human protease-activated receptor-4. Hybridoma (Larchmt) 2008; 27: 331-5.
53. Hammes SR, Coughlin SR. Protease-activated receptor-1 can mediate responses to SFLLRN in thrombin-desensitized cells: Evidence for a novel mechanism for preventing or terminating signaling by PAR1's tethered ligand. Biochemistry 1999; 38: 2486-93.
54. Faruqi TR, Weiss EJ, Shapiro MJ, Huang W, Coughlin SR. Structure-function analysis of protease-activated receptor 4 tethered ligand peptides. Determinants of specificity and utility in assays of receptor function. J Biol Chem 2000; 275: 19728-34.
55. Chen J, Bernstein HS, Chen M, Wang L, Ishii M, Turck CW, et al. Tethered ligand library for discovery of peptide agonists. J Biol Chem 1995; 270: 23398-401.
56. Vu TK, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991; 64: 1057-68.
57. Vassallo RR Jr, Kieber-Emmons T, Cichowski K, Brass LF. Structure-function relationships in the activation of platelet thrombin receptors by receptor-derived peptides. J Biol Chem 1992; 267: 6081-5.
58. Huang RS, Sorisky A, Church WR, Simons ER, Rittenhouse SE. Thrombin receptor-directed ligand accounts for activation by thrombin of platelet phospholipase C and accumulation of 3- phosphorylated phosphoinositides. J Biol Chem 1991; 266:18435-8.
59. Bernatowicz MS, Klimas CE, Hartl KS, Peluso M, Allegretto NJ, Seiler SM. Development of potent thrombin receptor antagonist peptides. J Med Chem 1996; 39: 4879-87.
60. Seiler SM, Peluso M, Tuttle JG, Pryor K, Klimas C, Matsueda GR, et al. Thrombin receptor activation by thrombin and receptorderived peptides in platelet and CHRF-288 cell membranes: Receptor-stimulated GTPase and evaluation of agonists and partial agonists. Mol Pharmacol 1996; 49:190-7.
61. Blackhart BD, Ruslim-Litrus L, Lu CC, Alves VL, Teng W, Scarborough RM, et al. Extracellular mutations of proteaseactivated receptor-1 result in differential activation by thrombin and thrombin receptor agonist peptide. Mol Pharmacol 2000; 58: 1178-87.
62. McLaughlin JN, Shen L, Holinstat M, Brooks JD, Dibenedetto E, Hamm HE. Functional selectivity of G protein signaling by agonist peptides and thrombin for the protease-activated receptor-1. J Biol Chem 2005; 280: 25048-59.
63. Trivedi V, Boire A, Tchernychev B, Kaneider NC, Leger AJ, O'Callaghan K, et al. Platelet matrix metalloprotease-1 mediates thrombogenesis by activating PAR1 at a cryptic ligand site. Cell 2009; 137: 332-43.
64. Riewald M, Petrovan RJ, Donner A, Mueller BM, Ruf W. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 2002; 296:1880-2.
65. Wang J, Li J. Activated protein C: A potential cardioprotective factor against ischemic injury during ischemia/reperfusion. Am J Transl Res 2009; 1: 381-92.
66. Ludeman MJ, Kataoka H, Srinivasan Y, Esmon NL, Esmon CT, Coughlin SR. PAR1 cleavage and signaling in response to activated protein C and thrombin. J Biol Chem 2005; 280: 13122-8.
67. Coughlin SR, Camerer E. PARticipation in inflammation. J Clin Invest 2003; 111: 25-7.
68. Busso N, Chobaz-Peclat V, Hamilton J, Spee P, Wagtmann N, So A. Essential role of platelet activation via protease activated receptor 4 in tissue factor-initiated inflammation. Arthritis Res Ther 2008; 10: R42.
69. Steinhoff M, Buddenkotte J, Shpacovitch V, Rattenholl A, Moormann C, Vergnolle N, et al. Proteinase-activated receptors: Transducers of proteinase-mediated signaling in inflammation and immune response. Endocr Rev 2005, 26:1-43.
70. Kahn ML, Zheng YW, Huang W, Bigornia V, Zeng D, Moff S, et al. A dual thrombin receptor system for platelet activation. Nature 1998; 394: 690-4.
71. Chiu PJ, Tetzloff GG, Foster C, Chintala M, Sybertz EJ. Characterization of in vitro and in vivo platelet responses to thrombin and thrombin receptor-activating peptides in guinea pigs. Eur J Pharmacol 1997; 321: 129-35.
72. Derian CK, Damiano BP, Addo MF, Darrow AL, D'Andrea MR, Nedelman M, et al. Blockade of the thrombin receptor proteaseactivated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates. J Pharmacol Exp Ther 2003; 304: 855-61.
73. Andrade-Gordon P, Derian CK, Maryanoff BE, Zhang HC, Addo MF, Cheung W, et al. Administration of a potent antagonist of protease-activated receptor-1 (PAR-1) attenuates vascular restenosis following balloon angioplasty in rats. J Pharmacol Exp Ther 2001; 298: 34-42.
74. Nakanishi-Matsui M, Zheng YW, Sulciner DJ, Weiss EJ, Ludeman MJ, Coughlin SR. PAR3 is a cofactor for PAR4 activation by thrombin. Nature 2000; 404: 609-13.
75. Weiss EJ, Hamilton JR, Lease KE, Coughlin SR. Protection against thrombosis in mice lacking PAR3. Blood 2002; 100: 3240-4.
76. Hamilton JR, Cornelissen I, Coughlin SR. Impaired hemostasis and protection against thrombosis in protease-activated receptor 4- deficient mice is due to lack of thrombin signaling in platelets. J Thromb Haemost 2004; 2:1429-35.
77. Sambrano GR, Weiss EJ, Zheng YW, Huang W, Coughlin SR. Role of thrombin signalling in platelets in haemostasis and thrombosis. Nature 2001; 413: 74-8.
78. Dupont A, Fontana P, Bachelot-Loza C, Reny JL, Bieche I, Desvard F, et al. An intronic polymorphism in the PAR-1 gene is associated with platelet receptor density and the response to SFLLRN. Blood 2003; 101: 1833-40.
79. Arnaud E, Nicaud V, Poirier O, Rendu F, Alhenc-Gelas M, Fiessinger JN, et al. Protective effect of a thrombin receptor (protease-activated receptor 1) gene polymorphism toward venous thromboembolism. Arterioscler Thromb Vasc Biol 2000; 20: 585-92.
80. De Candia E, Pecci A, Ciabattoni G, De Cristofaro R, Rutella S, Yao-Wu Z, et al. Defective platelet responsiveness to thrombin and protease-activated receptors agonists in a novel case of gray platelet syndrome: Correlation between the platelet defect and the alphagranule content in the patient and four relatives. J Thromb Haemost 2007; 5: 551-9.
81. Maryanoff BE, Zhang HC, Andrade-Gordon P, Derian CK. Discovery of potent peptide-mimetic antagonists for the human thrombin receptor, protease-activated receptor-1 (PAR-1). Curr Med Chem Cardiovasc Hematol Agents 2003; 1:13-36.
82. Das J, Kimball SD, Reid JA, Wang TC, Lau WF, Roberts DG, et al. Thrombin active site inhibitors: Chemical synthesis, in vitro and in vivo pharmacological profile of a novel and selective agent BMS-189090 and analogues. Bioorg Med Chem Lett 2002; 12: 41-4.
83. Kuliopulos A, Covic L. Blocking receptors on the inside: Pepducinbased intervention of PAR signaling and thrombosis. Life Sci 2003; 74: 255-62.
84. Seiler SM, Bernatowicz MS. Peptide-derived protease-activated receptor-1 (PAR-1) antagonists. Curr Med Chem Cardiovasc Hematol Agents 2003; 1: 1-11.
85. Chackalamannil, S., Chelliah, M.V., Wang, Y., Xia, Y. Preparation of bicyclic and tricyclic himbacine derivatives as thrombin receptor antagonists. WO2008042422 (2008).
86. Chackalamannil, S., Chelliah, M.V., Clasby, M.C., Xia, Y. Preparation of himbacine analogues as thrombin receptor antagonists. WO2003033501 (2003).
87. Chackalamannil, S., Clasby, M.C., Greenlee, W.J., Wang, Y., Xia, Y., Veltri, E.P., Chelliah, M. Preparation of naphthofuran thrombin receptor antagonists. WO2003089428 (2003).
88. Chackalamannil, S., Asberom, T., Xia, Y., Doller, D., Clasby, M.C., Czarniecki, M.F. Preparation of himbacine analogs as thrombin receptor antagonists. US6063847 (2000).
89. Chackalamannil, S., Chelliah, M.V., Xia, Y. Preparation of norseco himbacine derivatives as thrombin receptor antagonists. US2004152736 (2004).
90. Chackalamannil, S., Asberom, T., Xia, Y., Doller, D., Clasby, M.C., Czarniecki, M.F. Preparation of himbacine analogs for use as thrombin receptor antagonists. WO9926943 (1999).
91. Chelliah, M.V., Chackalamannil, S., Xia, Y., Clasby, M.C., Greenlee, W.J., Wang, Y., Veltri, E.P., Wu, W., Graziano, M.P., Kosoglou, T. Preparation of constrained himbacine analogs as thrombin receptor antagonists. US2005267155 (2005).
92. Chackalamannil, S., Wang, Y., Thiruvengadam, T.K., Zavialov, I., Li, T. Preparation of modified tricyclic himbacine derivatives as thrombin receptor antagonists. US2008085923 (2008).
93. Becker RC, Moliterno DJ, Jennings LK, Pieper KS, Pei J, Niederman A, et al. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: A randomised, double-blind, placebo-controlled phase II study. Lancet 2009; 373: 919-28.
94. Bonaca MP, Morrow DA. SCH 530348: A novel oral thrombin receptor antagonist. Future Cardiol 2009; 5: 435-42.
95. Chackalamannil S, Wang Y, Greenlee WJ, Hu Z, Xia Y, Ahn HS, et al. Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. J Med Chem 2008; 51: 3061-4.
96. Oestreich J. SCH-530348, a thrombin receptor (PAR-1) antagonist for the prevention and treatment of atherothrombosis. Curr Opin Investig Drugs 2009; 10: 988-96.
97. Feng DM, Veber DF, Connolly TM, Condra C, Tang MJ, Nutt RF. Development of a potent thrombin receptor ligand. J Med Chem 1995; 38: 4125-30.
98. Chintala M, Ahn H-S, Foster C, Agans J, Boykow G. Abstract 1710: Pharmacologic profile of SCH 530348, a novel oral antiplatelet agent selective for the protease-activated receptor-1 (PAR-1). Circulation 2008; 118: S374.
99. Kosoglou T, Reyderman L, Tiessen R, Fales RR, Cutler D, Keller R, et al. Trap-induced platelet aggregation following single and multiple rising oral doses of SCH 530348, a novel thrombin receptor antagonist, in healthy volunteers. Clin Pharmacol Ther 2009; 85: (Suppl 1), Abs PI-40.
100. Morrow DA, Scirica BM, Fox KA, Berman G, Strony J, Veltri E, et al. Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the thrombin-receptor antagonist in secondary prevention of atherothrombotic ischemic events (TRA 2 degrees P)-TIMI 50 trial. Am Heart J 2009; 158: 335-41, e333.
101. Committees TTCEaS. The thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA*CER) trial: Study design and rationale. Am Heart J 2009; 158: 327-34, e324.
102. Suzuki, S., Kotake, M., Miyamoto, M., Kawahara, T., Kajiwara, A., Hishinuma, I., Okano, K., Miyazawa, S., Clark, R., Ozaki, F. Preparation of 2-iminoimidazole derivatives as thrombin receptor antagonists. WO2002088092 (2002).
103. Suzuki, S., Kotake, M., Miyamoto, M., Kawahara, T., Kajiwara, A., Hishinuma, I., Okano, K., Miyazawa, S., Clark, R., Ozaki, F. Preparation of 2-iminopyrrolidine derivatives as thrombin receptor antagonists. WO2002085855 (2002).
104. Matsuoka T, Kogushi M, Kawata T, Kimura A, Chiba K-I, Musha T, et al. Inhibitory effect of E5555, an orally active thrombin receptor antagonist, on intimal hyperplasia following balloon injury. J Am Coll Cardiol 2004; 43: 68A.
105. Serebruany VL, Kogushi M, Dastros-Pitei D, Flather M, Bhatt DL. The in vitro effects of E5555, a protease-activated receptor (PAR)- 1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease. Thromb Haemost 2009; 102:111-9.
106. Suzuki, S., Kotake, M., Miyamoto, M., Kawahara, T., Kajiwara, A., Hishinuma, I., Okano, K., Miyazawa, S., Clark, R., Ozaki, F. Preparation of cyclic amidine derivatives as thrombin receptor antagonists. WO2002085850 (2002).
107. Suzuki, S., Kotake, M., Miyamoto, M., Kawahara, T., Kajiwara, A., Hishinuma, I., Okano, K., Miyazawa, S., Clark, R., Ozaki, F. Preparation of 2-iminoimidazole derivatives as platelet aggregation inhibitors. WO2002088094 (2002).
108. Kogushi M, Kobayashi H, Matsuoka T, Suzuki S, Kawahara T, Kajiwara A, et al. Anti-thrombotic and bleeding time effects of E5555, an orally active protease-activated receptor-1 antagonist, in guinea pigs. Circulation 2003, 108: 280.
109. Heinelt, U., Hofmeister, A., Czech, J. Imino-imidazo-pyridine derivatives having antithrombotic activity. US20090192150 (2009).
110. Kubo, K., Tobisu, M., Honda, E., Taniguchi, T., Fukase, Y., Kawamura, M., Nakayama, M. Triazole derivative and use thereof. US20090105253 (2009).
111. Perez, M., Lamothe, M., Le Grand, B., Letienne, R. Cinnamoylpeperazine derivatives and their use as PAR-1 antagonists. US20090176803 (2009).
112. Perez, M., Le Grand, B., Letienne, R. Protease activated receptor-1 antagonists for the treatment of atrial fibrillation. WO2008155335 (2008).
113. Perez, M., Lamothe, M., Le Grand, B., Letienne, R. Phenylpentadienoyl derivatives and their use as PAR 1 antagonists. WO2007147822 (2007).
114. Perez M, Lamothe M, Maraval C, Mirabel E, Loubat C, Planty B, et al. Discovery of novel protease activated receptors 1 antagonists with potent antithrombotic activity in vivo. J Med Chem 2009; 52: 5826-36.
115. Letienne R, Leparq-Panissie A, Calmettes Y, Nadal-Wollbold F, Perez M, Le Grand B. Antithrombotic activity of F 16618, a new PAR1 antagonist evaluated in extracorporeal arterio-venous shunt in the rat. Biochem Pharmacol 2010; 79(1): 1616-21.
116. Kuo, S.C., Huang, L.J., Lee, F.Y., Teng, C.M., Shih, M.L., Chen, H.S. Synthesis of N2-(substituted arylmethyl)-3-(substituted phenyl)indazoles as novel anti-angiogenic agents. US7514465 (2009).
117. Kuo, S.C., Lee, F.Y., Huang, T.M., Teng, C.M., Lee, O., Wu, C.Y., Hwang, C.S., Hung, C.Y. Synthesis of indole analogs of 1-benzyl-3-(5'-hydroxymethyl-2'-furyl) indazole (YC-1) as anti-platelet agents. US7176230 (2007).
118. Wu CC, Huang SW, Hwang TL, Kuo SC, Lee FY, Teng CM. YD-3, a novel inhibitor of protease-induced platelet activation. Br J Pharmacol 2000; 130:1289-96.
119. Wu CC, Hwang TL, Liao CH, Kuo SC, Lee FY, Lee CY, et al. Selective inhibition of protease-activated receptor 4-dependent platelet activation by YD-3. Thromb Haemost 2002; 87:1026-33.
120. Chen HS, Kuo SC, Teng CM, Lee FY, Wang JP, Lee YC, et al. Synthesis and antiplatelet activity of ethyl 4-(1-benzyl-1H-indazol-3-yl)benzoate (YD-3) derivatives. Bioorg Med Chem 2008; 16: 1262-78.
121. Wu CC, Teng CM. Comparison of the effects of PAR1 antagonists, PAR4 antagonists, and their combinations on thrombin-induced human platelet activation. Eur J Pharmacol 2006; 546: 142-7.
122. Peng CY, Pan SL, Guh JH, Liu YN, Chang YL, Kuo SC, et al. The indazole derivative YD-3 inhibits thrombin-induced vascular smooth muscle cell proliferation and attenuates intimal thickening after balloon injury. Thromb Haemost 2004; 92: 1232-9